Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Mesenchymal Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Mesenchymal Cell Neoplasm

Cancer Family

Mesenchymal Cell Neoplasm

CI-CAN-00000027Explore in graph →

Non-malignant413 active trials10 approved drugs208 evidence items

NCIt: C7059

Overview
Statistics
Survival
Genomics12
Variants & evidence208
Drugs20
Trials1848
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (108)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 108 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
· J Clin Oncol · 2003 · PMID 14645423 · validated civic_curation pubmed
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
· Eur J Cancer · 2006 · PMID 16624552 · validated civic_curation pubmed
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
· Lancet Oncol · 2018 · PMID 29606586 · validated civic_curation pubmed
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
· Nat Genet · 1998 · PMID 9462753 · validated civic_curation pubmed
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
· J Clin Oncol · 2017 · PMID 28787259 · validated civic_curation pubmed
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
· Ann Oncol · 2019 · PMID 30624546 · validated civic_curation pubmed
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
· Am J Hematol · 2018 · PMID 29352732 · validated civic_curation pubmed

Showing 1–25 of 108 publications

← Previous
1
2
…
5
Next →

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

· J Clin Oncol · 2005 · PMID 15928335 · validated civic_curation pubmed

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

· J Clin Oncol · 2006 · PMID 16954519 · validated civic_curation pubmed

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.

· Pharmacogenomics J · 2009 · PMID 19434073 · validated civic_curation pubmed

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.

· Cancer Res Treat · 2016 · PMID 26130666 · validated civic_curation pubmed

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

· Lancet Oncol · 2013 · PMID 23598171 · validated civic_curation pubmed

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

· J Clin Oncol · 2008 · PMID 18955451 · validated civic_curation pubmed

Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.

· Am J Pathol · 2008 · PMID 18832571 · validated civic_curation pubmed

CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics.

· Mod Pathol · 2012 · PMID 22766794 · validated civic_curation pubmed

Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.

· Nat Genet · 2013 · PMID 24162739 · validated civic_curation pubmed

Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data.

· Genes Chromosomes Cancer · 2012 · PMID 22034177 · validated civic_curation pubmed

PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.

· J Clin Oncol · 2002 · PMID 12039929 · validated civic_curation pubmed

Detection of HEY1-NCOA2 fusion by fluorescence in-situ hybridization in formalin-fixed paraffin-embedded tissues as a possible diagnostic tool for mesenchymal chondrosarcoma.

· Pathol Int · 2012 · PMID 23252872 · validated civic_curation pubmed

Are meningeal hemangiopericytoma and mesenchymal chondrosarcoma the same?: a study of HEY1-NCOA2 fusion.

· Am J Clin Pathol · 2013 · PMID 24124145 · validated civic_curation pubmed

Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.

· Clin Cancer Res · 2020 · PMID 31615936 · validated civic_curation pubmed

β-Catenin mutation status and outcomes in sporadic desmoid tumors.

· Oncologist · 2013 · PMID 23960186 · validated civic_curation pubmed

Specificity of fusion genes in adipocytic tumors.

· Anticancer Res · 2010 · PMID 20332486 · validated civic_curation pubmed

MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.

· Mod Pathol · 2016 · PMID 27562493 · validated civic_curation pubmed

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.

· J Clin Oncol · 2021 · PMID 34166060 · validated civic_curation pubmed